NASDAQ: TLIS

Talis Biomedical Corporation

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s February 2021 initial public offering (“IPO” or the “Offering”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 8, 2022.

If you purchased Talis securities and would like to join the action, please click “Join This Class Action.”

Class Period:Pursuant and/or traceable to the Company's IPO
If you purchased Talis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • the comparator assay in the primary study lacked sufficient sensitivity to support Talis’ Emergency Use Authorization (“EUA”) application for Talis One COVID-19 test;
  • as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test;
  • as a result, the Company’s commercialization timeline would be significantly delayed; and
  • as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Talis Biomedical Corporation
Stock Symbol: TLIS
Class Period: Pursuant and/or traceable to the Company's IPO
Court: United States District Court for the Northern District of California

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top